Precigen (PGEN)
Commercializes PAPZIMEOS while developing selected gene and cell therapies.
Something off on this page? Send us feedback.
Builds revenue around PAPZIMEOS, the FDA-approved treatment for adults with recurrent respiratory papillomatosis, as it moves into commercial operations. Selected programs in immuno-oncology, autoimmune disorders, and infectious diseases remain in development while resources are concentrated on the product launch.
Commercializes PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved, non-replicating adenoviral-vector immunotherapy for adults with recurrent respiratory papillomatosis. Administered by subcutaneous injection, the medicine marked the move from clinical development to commercial operations.
Develops gene- and cell-therapy programs through proprietary platforms across immuno-oncology, autoimmune disorders, and infectious diseases. Selected programs include PRGN-2009 and PRGN-3006, while enrollment in PRGN-3005 and PRGN-3007 was paused and UltraCAR-T spending was minimized.
Operates from Germantown, Maryland, and combined former business segments into one operating segment around the PAPZIMEOS launch. The business is shaped by commercialization of the approved medicine and the prioritization of resources among remaining development programs.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 5, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $14 | Target: $18 |
| May 28, 2026 | H.C. Wainwright | Target | Target: $11 | Target: $14 |
| May 14, 2026 | H.C. Wainwright | Target | Target: $6 | Target: $11 |
| Aug 15, 2025 | JP Morgan | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $38.2M · Total debt $98.3M · Total assets $170.3M · Shareholders' equity $43.6M
- Revenue
- $55.0M
- Operating income
- $22.6M
- Net income
- $20.1M
No dividends on record.
| Institutions | ≈ 39.13% | 140.10M shares | |
|---|---|---|---|
| 225 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 39.95% | 143.05M shares | |
| 12 holders · as of Aug 28, 2026 | |||
| Strategic holders | 9.51% | 34.05M shares | |
| 1 holder · as of Sep 23, 2025 | |||
| Other | ≈ 11.41% | 40.84M shares | |
| remainder | |||
358.04M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Randal J. Kirk1Insiderdirector, 10 percent owner | 37.41% | 133.96M | filed Mar 31, 2026 |
William H. Miller III Living Trust dated April 17, 2017Strategic | 9.51% | 34.05M | filed Sep 23, 2025 |
Patient Capital Management, LLCInstitution | 5.32% | 19.04M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 4.79% | 17.15M | as of Jun 30, 2026 |
State Street CorpInstitution | 3.35% | 12.00M | as of Jun 30, 2026 |
- Randal J. Kirk's transaction reports restate only vehicles that traded; the 2026 ownership statement (133.96M) is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | Jeffrey B. Kindler | director | −185,000 | $7.44 |
| Aug 21, 2026 | Nancy H. Agee | director | +3,411 | $7.23 |
| Aug 25, 2026 | Phil Tennant | officer: Chief Commercial Officer | −79,166 | $7.50 |
| Aug 25, 2026 | Rutul R. Shah | officer: Chief Operating Officer | −15,342 | $7.50 |
| Aug 21, 2026 | Rutul R. Shah | officer: Chief Operating Officer | −34,658 | $7.50 |
- Inovio Pharmaceuticals
Late-stage RRP DNA immunotherapy challenger
- Merck
Established PD-1 immunotherapy in cervical cancer
- Iovance Biotherapeutics
Tumor-infiltrating lymphocyte therapy developer
- Gilead Sciences
Kite’s commercial and investigational CAR-T portfolio
- Allogene Therapeutics
Off-the-shelf CAR-T platform developer
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Precigen | $7.91 | +2.78% | $2.75B | — | 15.1 | 32.0 | +6,161.7% |
| Inovio Pharmaceuticals | $1.29 | +3.63% | $85.7M | — | — | — | — |
| Merck | $151.63 | +1.42% | $369.24B | 119.6 | 17.6 | 5.6 | +5.1% |
| Iovance Biotherapeutics | $10.56 | +3.63% | $4.55B | — | — | 14.0 | +65.7% |
| Gilead Sciences | $152.62 | +1.37% | $186.93B | — | 16.8 | 6.1 | +10.2% |
| Allogene Therapeutics | $1.71 | +0.89% | $583.3M | — | — | 125.7 | — |
| Median | 119.6 | 17.2 | 10.1 | +10.2% |